Skip to main content

Advertisement

SpringerLink
Log in

Cancer Biomarkers for Integrative Oncology

  • Integrative Care (C Lammersfeld, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

There has been an increasing interest in using complementary and alternative medicine (CAM) approaches to treat cancer. It is therefore relevant and timely to determine if CAM biomarkers can be identified and developed to guide cancer diagnosis and treatment. Herein, we review the status of cancer biomarkers in CAM research and treatment to stimulate further research in this area.

Recent Findings

Studies on promising anti-cancer natural products, such as PHY906, honokiol, bryostatin-1, and sulforaphane have demonstrated the existence of potential cancer biomarker(s). Additional studies are required to further develop and ultimately validate these biomarkers that can predict clinical activity of the anti-cancer natural products used alone or in combination with chemotherapeutic agents.

Summary

A systematic approach is needed to identify and develop CAM treatment associated biomarkers and to define their role in facilitating clinical decision-making. The expectation is to use these biomarkers in determining potential options for CAM treatment, examining treatment effects and toxicity and/or clinical efficacy in patients with cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2010;2(45):45ra59.

    Article  PubMed  Google Scholar 

  2. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269(2):199–225.

    Article  CAS  PubMed  Google Scholar 

  3. Kunnumakkara AB, Bordoloi D, Harsha C, Banik K, Gupta SC, Aggarwal BB. Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. Clin Sci (Lond). 2017;131(15):1781–99.

    Article  CAS  Google Scholar 

  4. Samanta SK, Sehrawat A, Kim SH, Hahm ER, Shuai Y, Roy R, et al. Disease subtype-independent biomarkers of breast cancer chemoprevention by the ayurvedic medicine phytochemical withaferin A. J Natl Cancer Inst. 2017;109(6).

  5. • Battle TE, Arbiser J, Frank DA. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood. 2005;106(2):690–7 This study defined the molecular mechanism by which a natural product displays a therapeutic index in killing malignant B lymphocytes versus normal lymphocytes. It also showed how honokiol can overcome biologically important resistance mechanisms and synergize with conventional anti-cancer agents, all critical aspects for a novel therapeutic.

    Article  CAS  PubMed  Google Scholar 

  6. Hsu HYH, C.S. Commonly used Chinese herb formulas with illustrations. Oriental Healing Art Institute: Long Beach; 1980.

    Google Scholar 

  7. Li S. The Ben Cao Gang Mu: Chinese dition Univ. California Press; 2016.

  8. Tilton R, Paiva AA, Guan JQ, Marathe R, Jiang Z, van Eyndhoven W, et al. A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. Chin Med. 2010;5:30.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ye M, Liu SH, Jiang Z, Lee Y, Tilton R, Cheng YC. Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy. Rapid Commun Mass Spectrom. 2007;21(22):3593–607.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang W, Saif MW, Dutschman GE, Li X, Lam W, Bussom S, et al. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J Chromatogr A. 2010;1217(37):5785–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lam W, Jiang Z, Guan F, Hu R, Liu SH, Chu E, et al. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018). BMC Complement Altern Med. 2014;14:490.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Liu SH, Cheng YC. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. J Ethnopharmacol. 2012;140(3):614–23.

    Article  CAS  PubMed  Google Scholar 

  13. Lam W, Jiang Z, Guan F, Huang X, Hu R, Wang J, et al. PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. Sci Rep. 2015;5:9384.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Farrell MP, Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2003;2(4):253–6.

    Article  CAS  PubMed  Google Scholar 

  15. • Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O’Rourke M, et al. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2011;10(2):85–96 This was the first randomized, placebo-controlled clinical study to show that the Chinese herbal medicine PHY906 was able to significantly reduce the diarrhea, nausea/vomiting, and fatigue of irinotecan-based chemotherapy in patients with metastatic colorectal cancer. This study also showed that PHY906 did not alter the pharmacokinetic profile of the chemotherapy agents 5-fluorouracil and irinotecan.

    Article  CAS  PubMed  Google Scholar 

  16. Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine. 2010;17(3–4):161–9.

    Article  CAS  PubMed  Google Scholar 

  17. Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, et al. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 2009;29(10):4083–92.

    CAS  PubMed  Google Scholar 

  18. Saif M, Li J, Lamb L, Kaley K, Bussom S, Carbone R, et al. Phase II study of PHY906 plus capecitabine (CAP) in pts with gemcitabine-refractory pancreatic cancer (PC) and measurement of cytokines. J Clin Oncol. 2010;28(15_suppl):e14540-e.

    Article  Google Scholar 

  19. Alsamarai S, Ravage-Mass L, Kaley K, Dutschman G, Zhang W, Jiang Z, et al. A phase I study of PHY906 as a modulator of irinotecan (CPT-11) in patients with advanced solid tumors. J Clin Oncol. 2010;28(15_suppl):e13571-e.

    Article  Google Scholar 

  20. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003;278(37):35501–7.

    Article  CAS  PubMed  Google Scholar 

  21. • Wang X, Beitler JJ, Huang W, Chen G, Qian G, Magliocca KR, et al. Honokiol radiosensitizes squamous cell carcinoma of the head and neck by downregulation of survivin. Clin Cancer Res. 2017; This study demonstrated that increased expression of the pro-survival protein survivin is a negative prognostic indicator in squamous cell carcinoma of the head and neck, and may mediate resistance to radiation therapy. Downregulation of survivin in response to the natural product honokiol sensitizes these cells to radiation, suggesting an innovative, rational way to therapeutically exploit the activity of this drug.

  22. Avtanski BD, Arumugam N, Bonner MY, Arbiser JL, Saxena NK, Dipali S. Honokiol inhibits epithelial—mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol. 2014;8(3):565–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pearson HE, Iida M, Orbuch RA, McDaniel NK, Nickel KP, Kimple RJ, et al. Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol. Mol Cancer Ther. 2017.

  24. Jing P, Yongik L, Yian W, Ming Y. Honokiol targets mitochondria to halt cancer progression and metastasis. Mol Nutr Food Res. 2016;60(6):1383–95.

    Article  Google Scholar 

  25. Pan J, Lee Y, Zhang Q, Xiong D, Wan TC, Wang Y, et al. Honokiol decreases lung cancer metastasis through inhibition of the STAT3 signaling pathway. Cancer Prev Res. 2016.

  26. Krige D. Traditional medicine and healers in South Africa. J Eur Med Writers Assoc. 2009.

  27. Keck GE, Poudel YB, Cummins TJ, Rudra A, Covel JA. Total synthesis of bryostatin 1. J Am Chem Soc. 2011;133(4):744–7.

    Article  CAS  PubMed  Google Scholar 

  28. Matias D, Bessa C, Fátima Simões M, Reis CP, Saraiva L, Rijo P. Chapter 2 - Natural products as lead protein kinase c modulators for cancer therapy. In: Atta ur R, editor. Studies in natural products chemistry. 50: Elsevier; 2016. p. 45–79.

  29. Kennedy MJ, Prestigiacomo LJ, Tyler G, May WS, Davidson NE. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res. 1992;52(5):1278–83.

    CAS  PubMed  Google Scholar 

  30. Khan TK, Nelson TJ. Protein kinase C activator bryostatin-1 modulates proteasome function. J Cell Biochem. 2018;119:6894–904.

    Article  CAS  PubMed  Google Scholar 

  31. Jiang G, Dandekar S. Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retrovir. 2015;31(1):4–12.

    Article  CAS  PubMed  Google Scholar 

  32. • Battle TE, Frank DA. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to bryostatin 1. Blood. 2003;102:3016–24 This study demonstrated that a natural product from a marine organism can have a unique mechanism as an anti-cancer therapeutic, by inducing the terminal differentiation of malignant cells. This approach holds the potential to be more effective and less toxic than standard cytotoxic therapies. This study also delineated the novel molecular pathway by which bryostatin 1 mediates this biological effect.

    Article  CAS  PubMed  Google Scholar 

  33. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer. 1993;68:418–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer. 1995;72:461–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A. 1992;89(6):2399–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiol Biomark Prev. 1998;7(12):1091–100.

    CAS  Google Scholar 

  37. Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res. 2007;635(2–3):90–104.

    Article  CAS  PubMed  Google Scholar 

  38. Tang L, Zirpoli GR, Guru K, Moysich KB, Zhang Y, Ambrosone CB, et al. Consumption of raw cruciferous vegetables is inversely associated with bladder cancer risk. Cancer Epidemiol Biomark Prev. 2008;17(4):938–44.

    Article  CAS  Google Scholar 

  39. Tang L, Zirpoli GR, Guru K, Moysich KB, Zhang Y, Ambrosone CB, et al. Intake of cruciferous vegetables modifies bladder cancer survival. Cancer Epidemiol Biomark Prev. 2010;19(7):1806–11.

    Article  CAS  Google Scholar 

  40. Michaud DS, Clinton SK, Rimm EB, Willett WC, Giovannucci E. Risk of bladder cancer by geographic region in a U.S. cohort of male health professionals. Epidemiology. 2001;12(6):719–26.

    Article  CAS  PubMed  Google Scholar 

  41. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci E. Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol. 2000;152(12):1145–53.

    Article  CAS  PubMed  Google Scholar 

  42. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci EL. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst. 1999;91(7):605–13.

    Article  CAS  PubMed  Google Scholar 

  43. Veeranki OL, Bhattacharya A, Tang L, Marshall JR, Zhang Y. Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer. Curr Pharmacol Rep. 2015;1(4):272–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Atwell LL, Zhang Z, Mori M, Farris P, Vetto JT, Naik AM, et al. Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy. Cancer Prev Res (Phila). 2015;8(12):1184–91.

    Article  CAS  Google Scholar 

  45. Singh SV, Singh K. Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research. Carcinogenesis. 2012;33(10):1833–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Tang L, Li G, Song L, Zhang Y. The principal urinary metabolites of dietary isothiocyanates, N-acetylcysteine conjugates, elicit the same anti-proliferative response as their parent compounds in human bladder cancer cells. Anti-Cancer Drugs. 2006;17(3):297–305.

    Article  CAS  PubMed  Google Scholar 

  47. Zhang Y. Allyl isothiocyanate as a cancer chemopreventive phytochemical. Mol Nutr Food Res. 2010;54(1):127–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Houghton CA, Fassett RG, Coombes JS. Sulforaphane: translational research from laboratory bench to clinic. Nutr Rev. 2013;71(11):709–26.

    Article  PubMed  Google Scholar 

  49. Choi S, Lew KL, Xiao H, Herman-Antosiewicz A, Xiao D, Brown CK, et al. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. Carcinogenesis. 2007;28(1):151–62.

    Article  CAS  PubMed  Google Scholar 

  50. Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A. 2009;106(39):16663–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000;60(5):1426–33.

    CAS  PubMed  Google Scholar 

  52. Suppipat K, Park CS, Shen Y, Zhu X, Lacorazza HD. Sulforaphane induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cells. PLoS One. 2012;7(12):e51251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Jo GH, Kim GY, Kim WJ, Park KY, Choi YH. Sulforaphane induces apoptosis in T24 human urinary bladder cancer cells through a reactive oxygen species-mediated mitochondrial pathway: the involvement of endoplasmic reticulum stress and the Nrf2 signaling pathway. Int J Oncol. 2014;45(4):1497–506.

    Article  CAS  PubMed  Google Scholar 

  54. Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen JG, et al. Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem. 2013;329:163–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Talalay P, Fahey JW. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. J Nutr. 2001;131(11 Suppl):3027S–33S.

    Article  CAS  PubMed  Google Scholar 

  56. Dang YM, Huang G, Chen YR, Dang ZF, Chen C, Liu FL, et al. Sulforaphane inhibits the proliferation of the BIU87 bladder cancer cell line via IGFBP-3 elevation. Asian Pac J Cancer Prev. 2014;15(4):1517–20.

    Article  PubMed  Google Scholar 

  57. Abbaoui B, Riedl KM, Ralston RA, Thomas-Ahner JM, Schwartz SJ, Clinton SK, et al. Inhibition of bladder cancer by broccoli isothiocyanates sulforaphane and erucin: characterization, metabolism, and interconversion. Mol Nutr Food Res. 2012;56(11):1675–87.

    Article  CAS  PubMed  Google Scholar 

  58. Choi S, Singh SV. Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res. 2005;65(5):2035–43.

    Article  CAS  PubMed  Google Scholar 

  59. Bhattacharya A, Li Y, Shi Y, Zhang Y. Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. Carcinogenesis. 2013;34(11):2593–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Lee YM, Cho HJ, Ponnuraj SP, Kim J, Kim JS, Kim SG, et al. Phenethyl isothiocyanate inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammatory responses in mouse skin. J Med Food. 2011;14(4):377–85.

    Article  CAS  PubMed  Google Scholar 

  61. Shan Y, Wu K, Wang W, Wang S, Lin N, Zhao R, et al. Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells. Int J Oncol. 2009;34(4):1129–34.

    CAS  PubMed  Google Scholar 

  62. Tang L, Zhang Y. Dietary isothiocyanates inhibit the growth of human bladder carcinoma cells. J Nutr. 2004;134(8):2004–10.

    Article  CAS  PubMed  Google Scholar 

  63. Mukherjee P, Winter SL, Alexandrow MG. Cell cycle arrest by transforming growth factor beta1 near G1/S is mediated by acute abrogation of prereplication complex activation involving an Rb-MCM interaction. Mol Cell Biol. 2010;30(3):845–56.

    Article  CAS  PubMed  Google Scholar 

  64. Tong YH, Zhang B, Fan Y, Lin NM. Keap1-Nrf2 pathway: a promising target towards lung cancer prevention and therapeutics. Chronic Dis Transl Med. 2015;1(3):175–86.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Bricker GV, Riedl KM, Ralston RA, Tober KL, Oberyszyn TM, Schwartz SJ. Isothiocyanate metabolism, distribution, and interconversion in mice following consumption of thermally processed broccoli sprouts or purified sulforaphane. Mol Nutr Food Res. 2014;58(10):1991–2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Munday R, Munday CM. Induction of phase II detoxification enzymes in rats by plant-derived isothiocyanates: comparison of allyl isothiocyanate with sulforaphane and related compounds. J Agric Food Chem. 2004;52(7):1867–71.

    Article  CAS  PubMed  Google Scholar 

  67. • Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, et al. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Invest New Drugs. 2015;33(2):480–9 Based on results of their work demonstrating that sulforaphane inhibits AR signaling in prostate cancer cells, the current study reports results from the first clinical trial of sulforaphane-rich extracts in men with prostate cancer. The study was the first to report the safety of treatment and the effects of sulforaphane extract on PSA doubling time modulation. These are critical data of safety that inform future development of early-phase clinical trials in humans.

    Article  CAS  PubMed  Google Scholar 

  68. • Atwell LL, Hsu A, Wong CP, Stevens JF, Bella D, Yu TW, et al. Absorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract. Mol Nutr Food Res. 2015;59(3):424–33 These are critical data of bioavailability that inform future development of early-phase clinical trials in humans.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. • Cipolla BG, Mandron E, Lefort JM, Coadou Y, Della Negra E, Corbel L, et al. Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy. Cancer Prev Res (Phila). 2015;8(8):712–9 The current study was the first randomized clinical trials to report that daily administration of free sulforaphane shows promise in managing biochemical recurrences in prostate cancer after radical prostatectomy. These are critical data of safety and efficacy that inform future development of early-phase clinical trials in humans.

    Article  CAS  Google Scholar 

  70. Traka M, Gasper AV, Melchini A, Bacon JR, Needs PW, Frost V, et al. Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS One. 2008;3(7):e2568.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Egner PA, Chen JG, Wang JB, Wu Y, Sun Y, Lu JH, et al. Bioavailability of Sulforaphane from two broccoli sprout beverages: results of a short-term, cross-over clinical trial in Qidong, China. Cancer Prev Res (Phila). 2011;4(3):384–95.

    Article  CAS  Google Scholar 

  72. Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, Talalay P. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta. 2002;316(1–2):43–53.

    Article  CAS  PubMed  Google Scholar 

  73. Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Biomarkers in bladder cancer. BJU Int. 2010;105(5):608–13.

    Article  CAS  PubMed  Google Scholar 

  74. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Luque RJ, Alvarez-Kindelan J, Requena MJ, et al. Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Lett. 2006;242(2):266–72.

    Article  CAS  PubMed  Google Scholar 

  75. Ding W, Gou Y, Sun C, Xia G, Wang H, Chen Z, et al. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Urol Oncol. 2014;32(1):42 e13–9.

    Article  Google Scholar 

  76. Gasper AV, Al-Janobi A, Smith JA, Bacon JR, Fortun P, Atherton C, et al. Glutathione S-transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli. Am J Clin Nutr. 2005;82(6):1283–91.

    Article  CAS  PubMed  Google Scholar 

  77. Islam SS, Mokhtari RB, Akbari P, Hatina J, Yeger H, Farhat WA. Simultaneous targeting of bladder tumor growth, survival, and epithelial-to-mesenchymal transition with a novel therapeutic combination of acetazolamide (AZ) and sulforaphane (SFN). Target Oncol. 2016;11(2):209–27.

    Article  CAS  PubMed  Google Scholar 

  78. Santos LL, Amaro T, Pereira SA, Lameiras CR, Lopes P, Bento MJ, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol. 2003;29(1):74–80.

    Article  CAS  PubMed  Google Scholar 

  79. Mukherjee P, Cao TV, Winter SL, Alexandrow MG. Mammalian MCM loading in late-G(1) coincides with Rb hyperphosphorylation and the transition to post-transcriptional control of progression into S-phase. PLoS One. 2009;4(5):e5462.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Mackenzie GG, Queisser N, Wolfson ML, Fraga CG, Adamo AM, Oteiza PI. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer. 2008;123(1):56–65.

    Article  CAS  PubMed  Google Scholar 

  81. Baker M. Deceptive curcumin offers cautionary tale for chemists. Nature News. 2017;541(7636):144–5.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the past and present members of Dr. Y-C. Cheng’s laboratory group who were involved in the pre-clinical and translational studies on PHY906 and to all the clinical investigators, patients, and their families involved in the PHY906 clinical trials. The authors also thank Dr. Lyndsay Harris for the support and valuable comments, and to Dr. Laura K. Fogli for formatting this manuscript.

Funding

This research on PHY906 was supported in part by grants from the National Cancer Institute (grant nos. P01CA154295-01 and P30CA147904), the National Center for Complementary and Alternative Medicine, and a grant from the National Foundation for Cancer. Dr. David Frank was supported by NIH grant R01-CA160979.

Author information

Author notes

  1. David Frank, Nagi Kumar, Yung-Chi Cheng and Edward Chu contributed equally to this work.

Authors and Affiliations

  1. Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at the National Institutes of Health, 9609 Medical Center Drive, Rm. 4-W438, Rockville, MD, 20850, USA

    Aniruddha Ganguly

  2. Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, 02215, USA

    David Frank

  3. H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, 33612, USA

    Nagi Kumar

  4. Department of Pharmacology, Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, 06510, USA

    Yung-Chi Cheng

  5. Department of Medicine, Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15232, USA

    Edward Chu

Authors
  1. Aniruddha Ganguly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Frank
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nagi Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yung-Chi Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edward Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aniruddha Ganguly.

Ethics declarations

Conflict of Interest

Aniruddha Ganguly declares that he has no conflict of interest.

David Frank has received research funding from Gilead and Cstem; has received compensation from Kymera for service as a consultant; has a patent issued, licensed, and receives royalties for STAT Modulators; and has a patent pending for targeting the transcription factor NF-kB with harmine.

Nagi Kumar declares that she has no conflict of interest.

Yung-Chi Cheng is a fellow of the National Foundation for Cancer that partially supported PHY906 studies. He is a co-founder of Yiviva with the Yale University to further develop PHY906 (now known as Yiviva 906) for the treatment of various human cancers and other GI disorders.

Edward Chu is a member of the scientific advisory board of Yiviva.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Integrative Care

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ganguly, A., Frank, D., Kumar, N. et al. Cancer Biomarkers for Integrative Oncology. Curr Oncol Rep 21, 32 (2019). https://doi.org/10.1007/s11912-019-0782-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-019-0782-6

Keywords

Search

Navigation